World Wires · story 3790 · unverified · 1 source(s)

Mirum Pharmaceuticals announces positive phase 3 results for AZURE-1

Mirum Pharmaceuticals reports meeting the primary endpoint in the Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus infection.

Open in the desk

Coverage

• Mirum Pharmaceuticals announces positive phase 3 results for AZURE-1 GDELT crisis monitor · tier D · clear net · 2026-09-29 02:00 UTC

What this site indexes